Viatris报告说,2024年取得了强有力的成果,偿还了债务,但2025年的前景低于分析家的期望。 Viatris reports strong 2024 results, pays down debt, but 2025 outlook falls short of analysts' expectations.

一家制药公司Viatris报告说,2024年的财务结果强劲,超过了对自由现金流的预期,还清了37亿美元的债务。 Viatris, a pharmaceutical company, reported strong financial results for 2024, exceeding expectations for free cash flow and repaying $3.7 billion in debt. Viatris项目在2025年将EPS调整为2.12至2.26美元,总收入为13.5亿美元至140亿美元,低于分析员的估计。 For 2025, Viatris projects adjusted EPS of $2.12 to $2.26 and total revenues of $13.50 billion to $14.00 billion, below analysts' estimates. 该公司计划通过股票回购(500万至650万美元)和股利将资本返还给股东,在2025年3月18日支付季度股息为每股0.12美元。 The company plans to return capital to shareholders through share repurchases ($500M-$650M) and dividends, with a quarterly dividend of $0.12 per share payable on March 18, 2025.